Cancer Vaccines: Promising Therapeutics or an Unattainable Dream

• Main Authors: Howard Donninger, Chi Li, John W. Eaton, Kavitha Yaddanapudi
• Format: Article
• Language: English
• Published: MDPI AG 2021-06-01
• Series: Vaccines
• Subjects: cancer vaccines; preventative vaccines; therapeutic vaccines; immunotherapy; personalized vaccines
• Online Access: https://www.mdpi.com/2076-393X/9/6/668

The advent of cancer immunotherapy has revolutionized the field of cancer treatment and offers cancer patients new hope. Although this therapy has proved highly successful for some patients, its efficacy is not all encompassing and several cancer types do not respond. Cancer vaccines offer an alternate approach to promote anti-tumor immunity that differ in their mode of action from antibody-based therapies. Cancer vaccines serve to balance the equilibrium of the crosstalk between the tumor cells and the host immune system. Recent advances in understanding the nature of tumor-mediated tolerogenicity and antigen presentation has aided in the identification of tumor antigens that have the potential to enhance anti-tumor immunity. Cancer vaccines can either be prophylactic (preventative) or therapeutic (curative). An exciting option for therapeutic vaccines is the emergence of personalized vaccines, which are tailor-made and specific for tumor type and individual patient. This review summarizes the current standing of the most promising vaccine strategies with respect to their development and clinical efficacy. We also discuss prospects for future development of stem cell-based prophylactic vaccines.